Brief: Apontis Pharma AG Announces New Forecast 2023 And Details On Announced Restructuring Program
08/11/2023 19:03
Nov 8 (Reuters) - Apontis Pharma Ag APPHG.DE :
* EQS-ADHOC: APONTIS PHARMA AG WITH NEW FORECAST 2023 AND
DETAILS
ON ANNOUNCED RESTRUCTURING PROGRAM
* EXPECTS REVENUES OF EUR 36.1 MILLION AND EBITDA BEFORE
RESTRUCTURING EXPENSES OF EUR -8.6 MILLION IN 2023 FINANCIAL
YEAR.
* RESTRUCTURING EXPENSES ARE ESTIMATED TO TOTAL BETWEEN EUR
5.0
MILLION AND EUR 8.0 MILLION.
Source text for Eikon: ID:nEQ6PW6Pba
Further company coverage: APPHG.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apontis Pharma AG
See all newsBrief: Bruno Wohschlegel To Leave Apontis Pharma As CEO End Of August
Brief: APONTIS PHARMA Q1 EBITDA EUR 1.3 Million
Brief: Apontis Pharma Says Zentiva AG Submits Formal Request To Carry Out A Merger
Brief: Zentiva Says Amendeds Offer To Acquire Each Outstanding Share Of Apontis Pharma In Cash By Waiving Condition Of A Minimum Acceptance
Brief: Apontis Pharma: Zentiva To Launch Voluntary Public Purchase Offer At EUR 10.00 Per Share